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ABSTRACT
Introduction Observational studies suggest that physical 
activity lowers and sedentary behavior increases the risk 
of type 2 diabetes. Despite of some supportive trial data 
for physical activity, it is largely unresolved whether these 
relations are causal or due to bias.
Objective We investigated the associations between 
accelerometer- based physical activity and sedentary 
behavior with type 2 diabetes and several glycemic traits 
using two- sample Mendelian randomization analysis.
Research design and methods Single nucleotide 
polymorphisms (SNPs) associated at p<5×10−8 
with accelerometer- based physical activity average 
accelerations, vigorous physical activity (fraction of 
accelerations >425 milligravities), and sedentary 
behavior (metabolic equivalent task ≤1.5) in a genome- 
wide analysis of the UK Biobank served as instrumental 
variables.
Outcomes Type 2 diabetes, hemoglobin A1c (HbA1c), 
fasting glucose, homeostasis model assessment of 
beta- cell function (HOMA- B), and homeostasis model 
assessment of insulin resistance (HOMA-IR).
Results Physical activity and sedentary behavior were 
unrelated to type 2 diabetes, HbA1c, fasting glucose, 
HOMA- B, and HOMA- IR. The inverse variance weighted 
ORs per SD increment for the association between average 
accelerations and vigorous physical activity with type 2 
diabetes were 1.00 (95% CI 0.94 to 1.07, p=0.948) and 
0.83 (95% CI 0.56 to 1.23, p=0.357), respectively. These 
results were confirmed by sensitivity analyses using 
alternative MR- methods to test the robustness of our 
findings.
Conclusions Based on these results, genetically predicted 
objectively measured average or vigorous physical 
activity and sedentary behavior is not associated with 
type 2 diabetes risk or with glycemic traits in the general 
population. Further research is required to deepen the 
understanding of the biological pathways of physical 
activity.
INTRODUCTION
Type 2 diabetes is one of the most frequent 
non- communicable diseases, with an esti-
mated 463 million cases worldwide in 2019; 
this number is projected to increase to 578 
million by 2030.1 A variety of observational 
cohort studies found an inverse associa-
tion between physical activity (PA) and type 
2 diabetes, while only a few investigations 
reported no association.2 Studies showed 
a reduced risk with greater moderate and 
vigorous activity, but data were less consis-
tent for low intensity activity such as walking.2 
Subsequent studies focused on specific types 
of PA and possible dose–response relation-
ships.2 In addition, meta- analyses of interven-
tion studies revealed that exercise programs 
induce changes in glycemic traits such as 
fasting blood glucose and glycated hemo-
globin levels.3 However, the beneficial effect 
of PA seems to depend on the duration of 
exercise and not on the type and intensity of 
activity.3
Previous observational studies have relied 
on self- report measures of PA, which are 
Significance of this study
What is already known about this subject?
 ► Based on randomized controlled trials mostly con-
ducted in people with high risk for diabetes, there is 
no clear evidence that physical activity alone or diet 
alone compared with standard treatment influences 
the risk for type 2 diabetes.
What are the new findings?
 ► In a two- sample Mendelian randomization study, 
neither genetically predicted objectively measured 
average and vigorous physical activity nor seden-
tary behavior were significantly associated with 
type 2 diabetes and glycemic traits in the general 
population.
How might these results change the focus of 
research or clinical practice?
 ► Further investigation is necessary to deepen the 
understanding of the biologic pathways of physical 
activity.
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prone to recall and response biases and may attenuate 
‘true’ associations with the outcome.4 5 There is evidence 
that self- reported and objective measures of PA can yield 
discrepant estimates.4 6–8 Large epidemiologic studies 
usually lack objective measurements of PA; however, the 
UK Biobank is an exception. In approximately 100 000 
study participants, PA was measured using a wrist acceler-
ometer that study participants wore for 7 days.9 Although 
objective methods to measure PA help address measure-
ment error, observational studies can be subject to other 
biases including residual confounding and reverse 
causality.
Mendelian randomization (MR) may provide another 
line of evidence concerning the roles of PA and seden-
tary behaviors (SBs) in type 2 diabetes. MR tests the 
effects of PA on type 2 diabetes using genetic variants as 
instruments that are explicitly associated with the expo-
sure PA and exert an effect on type 2 diabetes only via 
the exposure. Because variants are randomly allocated 
from parents to offspring at conception, they are less 
susceptible to environmental confounding and reverse 
causation than traditional observational studies.10 
Because genetic variants instrument for long- term levels 
of PA, regression dilution bias is less likely in MR studies.11 
Moreover, objectively measured PA is more heritable12 
than self- reported PA and thus more powerfully instru-
mented by single nucleotide polymorphism (SNPs) in the 
MR context.13 We performed two- sample MR analyses to 
investigate the relationship between accelerometer- based 
average accelerations, vigorous PA (fraction of accelera-
tions >425 milligravities), and SB with type 2 diabetes and 
glycemic traits, namely hemoglobin A1c (HbA1c), fasting 
blood glucose, homeostasis model assessment of beta- cell 
function (HOMA- B), and homeostasis model assessment 
of insulin resistance (HOMA- IR).
METHODS
The study design had five components: (1) identifica-
tion of genetic variants to serve as instrumental variables 
for PA and SB; (2) acquisition of instrumenting SNP 
outcome summary data from genome- wide association 
studies of type 2 diabetes, HbA1c levels, fasting glucose 
levels, HOMA- B, and HOMA- IR; (3) harmonization of 
SNP exposure and SNP outcome datasets; (4) statistical 
analysis; and (5) evaluation of MR analysis assumptions 
and sensitivity analyses.
Assessment of PA in UK Biobank
Data regarding different types of PA were gathered in the 
UK Biobank, a large prospective cohort study including 
approximately 500 000 men and women (ages 40–69 
years) living in the UK. Recruitment from 22 centers 
across the UK was performed between 2006 and 2010.14 
All study participants provided written informed consent.
In approximately 100 000 study participants, 
accelerometer- based PA data (Axivity AX3 wrist- worn 
accelerometer) were gathered.9 We used genetic variants 
proxying two accelerometer- based PA measures: average 
accelerations (mean acceleration in milligravities) and 
the fraction of accelerations >425 milligravities,12 the 
latter corresponding to an equivalent of vigorous PA 
(≥6 metabolic equivalent tasks (METs)). Accelerometer- 
based SB was defined as a MET ≤1.50.15
Selection of instrumental variables for PA
Most UK Biobank participants were genotyped with the 
Affymetrix UK Biobank Axiom Array (Santa Clara, Cali-
fornia, USA), while about 10% were genotyped with the 
Affymetrix UK BiLEVE Axiom Array.16
We initially selected eight SNPs associated with average 
accelerations and eight SNPs associated with vigorous 
PA at a genome- wide significance level (p<5×10−8) in 91 
084 UK Biobank participants.12 In addition, we selected 
six SNPs associated with SB at p<5×10−8.15 We looked 
up each instrument SNP and its proxies (r²>0.8) in the 
PhenoScanncer genome- wide association study (GWAS) 
database (http:// phenoscanner. medschl. cam. ac. uk)17 
to assess any previous associations (p<1×10−8) with the 
outcomes or potential confounders. Smoking was consid-
ered a relevant confounder.18 19 We identified one of 
the SNPs for average accelerations (rs28749810) nomi-
nally associated with type 2 diabetes and the metabolic 
syndrome, respectively. After removing this SNP, seven, 
eight, and six SNPs were used as instrumental variables 
for average accelerations, vigorous PA, and SB in the 
primary analysis.
GWAS summary data for outcomes
Summary data for the associations of genetic variants 
with type 2 diabetes were obtained from a GWAS meta- 
analysis of 32 studies including 898 130 individuals of 
European ancestry from the Diabetes Genetics Repli-
cation And Meta- analysis (DIAGRAM Consortium; 74 
124 type 2 diabetes cases and 824 006 controls).20 For 
HbA1c, summary data from a publication by Wheeler 
et al21 based on 123 665 diabetes- free participants’ data 
from the Meta- Analyses of Glucose and Insulin- related 
Traits Consortium (MAGIC) were used. Summary data 
for fasting glucose (sample size n=58 074), HOMA- B 
(n=36 466), and HOMA- IR (n=37 037) were drawn from 
publications by Manning et al22 and Dupuis et al23 based 
on data of diabetes- free individuals of European ancestry 
from the MAGIC. The GWAS for the outcomes did not 
include data from the UK Biobank. Online supplemental 
tables 2–4 provide associations of genome- wide signifi-
cant harmonized SNPs for accelerometer- based PA and 
SB with type 2 diabetes and glycemic traits.
Data availability
The present study is based on summary- level data that 
have been made publicly available. In all original studies, 
ethical approval had been obtained. The summary statis-
tics for the PA and SB GWAS is available at https:// klimen-
tidis. lab. arizona. edu/ content/ data and at https:// doi. 
org/ 10. 5287/ bodleian: yJp6zZmdj. The summary data 
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for the type 2 diabetes GWAS are available at http:// 
diagram- consortium. org/ downloads. html, while for the 
HbA1c, fasting glucose, HOMA- B and HOMA- IR GWASs, 
summary data are available at www. magicinvestigators. 
org/ downloads.
Statistical power
The a priori statistical power for the binary trait was 
calculated according to Burgess24 and for continuous 
traits according to Deng.25
The eight SNPs for average accelerations explained 
0.25%, and the eight SNPs for vigorous activity explained 
0.25% of the phenotypic variance. The analyses were 
sufficiently powered to identify associations between 
the different exposure variables and outcomes (online 
supplemental table 6).
Statistical analyses
The principal analysis was conducted using a multipli-
cative random effects inverse- variance weighted (IVW) 
method, which allows for each SNP to have different mean 
effects.26 The results for the outcome type 2 diabetes are 
presented as ORs and 95% CIs per 1 SD increment in 
average accelerations and vigorous PA or SB. One SD 
of objectively measured PA in the UK Biobank study 
has been reported to be approximately 8 milligravities 
(or 0.08 m/s2) of acceleration in a mean 5 s window 
of analyzed accelerometer data.15 A 1- SD increment in 
average accelerations (8.14 milligravities or 0.08 m/s²) 
approximates to about 3 MET- hour/day,27 with one MET 
equal to the metabolic cost of sitting quietly.28The results 
for the continuous outcomes are presented as β-estimates 
and 95% CIs per SD of objectively measured PA or SB.
One key assumption for IVW to produce a valid esti-
mate is that there is no other way SNPs could affect the 
outcome than through the exposure. Violations of this 
assumption through horizontal pleiotropy can intro-
duce bias, whereby the instruments exert an effect on 
the outcome independent of the exposure. To examine 
possible violations of this assumption, we checked each 
candidate SNP and its proxies (r²>0.8) in PhenoScanner 
(online supplemental table 5) for previously reported 
associations (p<5×10−8) with confounders. The presence 
of pleiotropy was further investigated using between- 
instrument heterogeneity of the IVW estimates based on 
a modified Cochran’s Q statistic (online supplemental 
table 7). If the pleiotropy is ‘balanced’ (ie, pleiotropic 
effects are independent in the magnitude of the SNP–
exposure associations, and its mean is zero), the effect 
can be reliably estimated by the multiplicative random 
effects IVW method. However, if the mean pleiotropic 
effect is non- zero, as shown by the presence of a devia-
tion from a zero intercept of an MR Egger regression, 
robust MR methods are indicated. Thus, IVW results 
were compared with other MR methods to address the 
violations of specific instrumental variable assumptions: 
weighted median MR- Pleiotropy RESidual Sum and 
Outlier (MR- PRESSO) and MR Mixture. The weighted 
median approach selects the median MR estimate as the 
causal estimate.29 To detect and correct for any outliers 
reflecting likely pleiotropic biases for all reported results, 
the MR- PRESSO method was applied.30 For sedentary 
behavior, there were less than five variants in combina-
tion with fasting glucose, HOMA- B and HOMA- IR. The 
MR- PRESSO method is based on the assumption that at 
least 50% of the variants are valid instruments relying on 
the Instrument Strength Independent of Direct Effect 
(InSIDE) condition. Thus, with less than five SNPs, the 
MR- PRESSO results were not very meaningful, and there-
fore, we omitted this analysis. The MRMix approach is a 
robust MR analysis tool that has the ability to trade off 
bias and efficiency for estimation of causal effects in the 
presence of invalid instruments.31
We performed leave- one- out analyses and exclusion of 
potentially pleiotropic SNPs to rule out possible pleio-
tropic effects (see online supplemental tables 8–10). The 
study was not preregistered. Analyses were performed 
using the TwoSampleMR (V.0.4.25)32 and MRPRESSO 
(V.1.0) packages in R (V.3.6.1). Reporting follows the 
Strengthening the Reporting of Observational Studies in 
Epidemiology statement.33
ETHICS APPROVAL
In the present study, publicly available summary statis-
tics were used, and therefore, no ethical approval was 
required.
RESULTS
Accelerometer-based PA and type 2 diabetes and glycemic 
traits
Average accelerations were unrelated to type 2 diabetes 
(IVW OR per 1 SD: 1.00; 95% CI 0.94 to 1.07), HbA1c 
(IVW β-estimate per 1 SD: 0.001; 95% CI −0.007 to 0.01), 
fasting glucose (IVW β-estimate per 1 SD: −0.001; 95% 
CI −0.017 to 0.015), HOMA- B (IVW β-estimate per 1 SD: 
−0.002; 95% CI −0.021 to 0.017), and HOMA- IR (IVW 
β-estimate per 1 SD: −0.001; 95% CI −0.019 to 0.016 
(table 1)) across all MR methods.
We also found no evidence that vigorous PA was asso-
ciated with type 2 diabetes (IVW OR per 1 SD: 0.83; 95% 
CI 0.56 to 1.23). Also, there was no association between 
vigorous PA and the investigated glycemic traits HbA1c, 
fasting glucose, HOMA- B, and HOMA- IR (table 2).
Accelerometer-based SB and type 2 diabetes and glycemic 
traits
We found that genetically predicted SB was unrelated to 
type 2 diabetes (IVW OR per 1 SD: 0.86; 95% CI 0.69 to 
1.08) and all the other investigated outcomes (table 3). 
This result was confirmed across all MR methods.
We conducted a series of sensitivity analyses to assess 
the robustness of the results. The F statistics for the 
genetic instruments were 30 or higher, consistent with an 
absence of weak instrument bias (online supplemental 
table 1).
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The intercept test from MR- Egger regression suggested 
no presence of pleiotropy (online supplemental table 
11). The estimates from the weighted median approach 
were consistent with the estimates from the IVW models, 
and the MR- PRESSO test identified no pleiotropic SNPs. 
Furthermore, the results from the leave- one- out analysis 
did not reveal any influential SNPs driving the associa-
tions (online supplemental table 8–10).
DISCUSSION
In this MR study, genetic predisposition to accelerometer- 
based average PA, vigorous PA and SB were not associ-
ated with the risk of type 2 diabetes. Furthermore, the 
present results did not provide clear evidence for a rela-
tionship between the different PA measures or SB and 
insulin resistance, beta- cell function, HbA1c as well as 
fasting glucose.
Our findings are not consistent with most previous 
observational studies and meta- analyses showing 
a protective association of PA with type 2 diabetes 
risk.2 34 A recent systematic review and dose- response 
meta- analysis2 reported a 39% risk reduction (95% CI 
0.51 to 0.74) when comparing high with low self- reported 
vigorous PA, with moderate heterogeneity across the 
included eight prospective observational studies in that 
subanalysis (I2=73%) and varying levels of adjustment 
for confounding factors. The discrepancies to our results 
might be attributable to residual confounding due to 
unmeasured or imprecisely measured confounders 
in observational studies. Furthermore, our MR anal-
ysis reflect long- term/lifelong PA in contrast to studies 
using short- term self- reported PA habits or PA interven-
tions as exposure. Usually, higher PA is linked to other 
healthy lifestyle factors (healthier diet, lower prevalence 
of obesity and smoking).35 The ability to disentangle the 
impact of highly correlated healthy lifestyle habits from 
each other and from other positive effects associated 
with PA and subsequently with a lower risk of diabetes 
(eg, lower blood pressure and weight, improved lipid 
profile, and mental well- being) may be limited when 
using conventional multivariable regression methods.36 
Furthermore, the association between PA and type 2 




SNPs OR/beta 95% CI P value Outcome
Inverse variance weighted (multiplicative 
random effects)
7 1.00 (0.94 to 1.07) 0.948 Type 2 diabetes
Weighted median 7 1.01 (0.97 to 1.06) 0.562 Type 2 diabetes
MR- PRESSO: outlier corrected 4 1.03 (1.01 to 1.06) 0.103 Type 2 diabetes
MRMix 7 1.52 (1.14 to 2.03) 0.004 Type 2 diabetes
Inverse variance weighted (multiplicative 
random effects)
5 0.001 (-0.007 to 0.01) 0.767 HbA1c
Weighted median 5 0.000 (−0.01 to 0.01) 0.968 HbA1c
MR- PRESSO: raw 5 0.001 (−0.007 to 0.01) 0.782 HbA1c
MRMix 5 0.035 (−0.917 to 0.987) 0.943 HbA1c
Inverse variance weighted (multiplicative 
random effects)
5 −0.001 (−0.017 to 0.015) 0.914 Fasting glucose
Weighted median 5 0.002 (−0.019 to 0.023) 0.861 Fasting glucose
MR- PRESSO: raw 5 −0.001 (−0.012 to 0.01) 0.886 Fasting glucose
MRMix 5 −0.010 (−0.204 to 0.184) 0.919 Fasting glucose
Inverse variance weighted (multiplicative 
random effects)
5 −0.002 (−0.021 to 0.017) 0.811 HOMA- B
Weighted median 5 −0.010 (−0.03 to 0.009) 0.294 HOMA- B
MR- PRESSO: raw 5 −0.002 (−0.021 to 0.017) 0.822 HOMA- B
MRMix 5 −0.360 (−0.698 to −0.022) 0.037 HOMA- B
Inverse variance weighted (multiplicative 
random effects)
5 −0.001 (−0.019 to 0.016) 0.871 HOMA- IR
Weighted median 5 −0.003 (−0.026 to 0.02) 0.786 HOMA- IR
MR- PRESSO: raw 5 −0.001 (−0.018 to 0.015) 0.875 HOMA- IR
MRMix 5 −0.010 (−0.269 to 0.249) 0.940 HOMA- IR
HbA1c, hemoglobin A1c; HOMA- B, homeostasis model assessment of beta- cell function; HOMA- IR, homeostasis model assessment of 
insulin resistance ; MR- PRESSO, MR- Pleiotropy RESidual Sum and Outlier; SNPs, single nucleotide polymorphisms.
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diabetes in observational studies might be due to reverse 
causation. Individuals screened for high risk of type 
2 diabetes or with a diagnosis of pre- diabetes possibly 
change their lifestyle to delay or prevent a manifestation 
of the disease.37 38 A change in lifestyle might include 
increasing levels of PA in addition to diet changes, weight 
loss, and quitting smoking.37 38
In an exposure- wide umbrella review of meta- analyses 
(including observational studies) regarding risk factors 
for type 2 diabetes, the association between seden-
tary time and risk of type 2 diabetes was supported by 
convincing evidence.39 Another systematic review and 
meta- analysis on the association between self- reported 
SB and different health outcomes found an increased 
risk for incident type 2 diabetes with higher levels of 
total sitting as well as TV viewing time, independent 
of PA.40 This finding was not replicated in the present 
study. However, in that meta- analysis, there was substan-
tial heterogeneity in exposure measurement and unmea-
sured confounding was likely,40 and thus it is difficult to 
ascertain causality. It is conceivable that in SB studies, 
confounding by socioeconomic status is more likely than 
in PA studies because TV time is strongly negatively asso-
ciated with education level.41
A number of randomized controlled trials (RCTs) 
have examined the effect of exercise interventions on 
glycemic traits. However, the majority of these RCTs used 
an intervention that combined exercise and diet compo-
nents, which make it difficult to attribute the effect to 
PA42; only one RCT focused exclusively on PA interven-
tion.43 Recently, a Cochrane Intervention Review of 12 
RCTs with a total of 5238 persons on the issue whether 
PA, diet or both can prevent or delay type 2 diabetes and 
its associated complications was published.42 Most of the 
trials included persons at increased risk of type 2 diabetes 
and the duration of the intervention varied between 2 
and 6 years. Only one trial compared diet with PA in one 
of its trial arms.44 There was no clear evidence that diet 
alone or PA alone compared with standard treatment 
influences the risk for type 2 diabetes,42 and the overall 
quality of evidence was very low. Our study confirms 
this finding by showing that objectively measured PA of 
Table 2 Mendelian randomization (MR) estimates between accelerometer- based vigorous PA (fraction of accelerations>425 
milli- gravities) and type 2 diabetes and glycemic traits
Method
No. of 
SNPs OR/beta 95% CI P value Outcome
Inverse variance weighted (multiplicative 
random effects)
8 0.83 (0.56 to 1.232) 0.357 Type 2 diabetes
Weighted median 8 0.80 (0.58 to 1.11) 0.177 Type 2 diabetes
MR- PRESSO: outlier corrected 6 0.86 (0.60 to 1.21) 0.421 Type 2 diabetes
MRMix 8 1.45 (0.86 to 2.44) 0.165 Type 2 diabetes
Inverse variance weighted (multiplicative 
random effects)
6 −0.018 (−0.085 to 0.05) 0.606 HbA1c
Weighted median 6 0.016 (−0.07 to 0.102) 0.717 HbA1c
MR- PRESSO: raw 6 −0.018 (−0.079 to 0.043) 0.595 HbA1c
MRMix 6 −0.035 (−0.169 to 0.099) 0.609 HbA1C
Inverse variance weighted (multiplicative 
random effects)
6 0.065 (−0.11 to 0.24) 0.469 Fasting glucose
Weighted median 6 0.059 (−0.148 to 0.266) 0.578 Fasting glucose
MR- PRESSO: raw 6 0.065 (−0.11 to 0.24) 0.502 Fasting glucose
MRMix 6 −0.010 (−0.574 to 0.554) 0.972 Fasting glucose
Inverse variance weighted (multiplicative 
random effects)
6 0.069 (−0.071 to 0.209) 0.336 HOMA- B
Weighted median 6 0.013 (−0.17 to 0.197) 0.886 HOMA- B
MR- PRESSO: raw 6 0.069 (−0.071 to 0.209) 0.380 HOMA- B
MRMix 6 0.110 (−0.902 to 1.122) 0.831 HOMA- B
Inverse variance weighted (multiplicative 
random effects)
6 0.102 (−0.111 to 0.316) 0.349 HOMA- IR
Weighted median 6 −0.041 (−0.258 to 0.176) 0.708 HOMA- IR
MR- PRESSO: raw 6 0.102 (−0.111 to 0.316) 0.392 HOMA- IR
MRMix 6 −0.030 (−0.455 to 0.395) 0.890 HOMA- IR
HbA1c, hemoglobin A1c; HOMA- B, homeostasis model assessment of beta- cell function; HOMA- IR, homeostasis model assessment of 
insulin resistance ; MR- PRESSO, MR- Pleiotropy RESidual Sum and Outlier; PA, physical activity; SNPs, single nucleotide polymorphisms.
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different intensities alone does not significantly reduce 
the risk of type 2 diabetes.
We also found no associations between objectively 
measured PA levels or SB and various glycemic traits. 
RCTs on this topic have yielded inconsistent results. In a 
systematic review and meta- analysis of randomized trials 
including 7487 participants aged 18–90 years (78.1% 
free of diabetes) based on 160 RCTs, moderate to long 
duration exercise training (2 weeks–2 years)45 had a 
protective effect on insulin resistance (HOMA- IR) and 
HbA1c but not on fasting glucose levels.45 Other system-
atic reviews and meta- analyses also suggested a protective 
effect of PA on insulin resistance. However, the quality 
of the included studies in those meta- analyses was mostly 
poor (high risk of bias),46 and the quality of evidence was 
low or very low for all outcomes.47
In addition, a systematic review and meta- analysis 
reported inverse relations of HbA1c and insulin to 
resistance exercise training intensity,47 and other meta- 
analyses found a reduction in fasting glucose levels 
after resistance exercise interventions in non- diabetic 
persons47 or a reduction of fasting glucose and HbA1c 
in physically active persons with type 2 diabetes or meta-
bolic syndrome only.46 Another systematic review and 
meta- analysis supported a decrease in HbA1c levels 
in favor of the physically active group (effect size 0.32; 
95% CI 0.01 to 0.62) noting substantial heterogeneity 
(I2=63.2%; p=0.008).48
Our MR analysis found no effect of average PA, 
vigorous PA and SB on glycemic traits. This seems plau-
sible because it is unlikely that PA will have a significant 
effect on these glycemic traits in the normal range in 
non- diabetic individuals. Most previous RCTs investi-
gating the effects of PA on fasting glucose and HbA1c 
levels were conducted in high- risk groups, such as indi-
viduals with pre- diabetes or obesity or people with mani-
fest type 2 diabetes. Hence, from observational studies 
and RCTs on this issue, it is not clear so far whether asso-
ciations between PA and type 2 diabetes are causal or 
biased due to self- report measurement error, residual 
confounding, reverse causality, or ascertainment bias in 
RCTs.
The findings of our two- sample MR study regarding the 
outcome type 2 diabetes are in line with results reported 
by Doherty et al.15 In that study, the MR analysis on the 
causal association between moderate accelerometer 
measured PA and diabetes in UK Biobank participants 
who were not in the accelerometer discovery dataset 
Table 3 Mendelian randomization (MR) estimates between accelerometer- based sedentary behavior (MET ≤1.5) and type 2 
diabetes and glycemic traits
Method
No. of 
SNPs OR/beta 95% CI P value Outcome
Inverse variance weighted (multiplicative 
random effects)
5 0.86 (0.69 to 1.08) 0.190 Type 2 diabetes
Weighted median 5 0.80 (0.60 to 1.08) 0.141 Type 2 diabetes
MR- PRESSO: raw 6 0.86 (0.69 to 1.08) 0.260 Type 2 diabetes
MRMix 6 1.00 (0.58 to 1.73) 1.000 Type 2 diabetes
Inverse variance weighted (multiplicative 
random effects)
4 0.010 (−0.078 to 0.099) 0.818 HbA1c
Weighted median 4 0.030 (−0.069 to 0.129) 0.553 HbA1c
MR- PRESSO: raw 5 0.010 (−0.078 to 0.099) 0.833 HbA1c
MRMix 5 0.025 (−0.130 to 0.180) 0.751 HbA1c
Inverse variance weighted (multiplicative 
random effects)
3 0.014 (−0.142 to 0.171) 0.856 Fasting glucose
Weighted median 3 0.045 (−0.144 to 0.234) 0.643 Fasting glucose
MRMix 4 0.025 (−0.185 to 0.235) 0.816 Fasting glucose
Inverse variance weighted (multiplicative 
random effects)
3 0.001 (−0.264 to 0.267) 0.991 HOMA- B
Weighted median 3 0.126 (−0.068 to 0.319) 0.203 HOMA- B
MRMix 4 0.230 (−0.122 to 0.582) 0.200 HOMA- B
Inverse variance weighted (multiplicative 
random effects)
3 0.023 (−0.363 to 0.409) 0.907 HOMA- IR
Weighted median 3 0.113 (−0.154 to 0.38) 0.407 HOMA- IR
MRMix 4 0.320 (−0.078 to 0.718) 0.115 HOMA- IR
HbA1c, hemoglobin A1c; HOMA- B, homeostasis model assessment of beta- cell function; HOMA- IR, homeostasis model assessment 
of insulin resistance ; MET, metabolic equivalent task; MR- PRESSO, MR- Pleiotropy RESidual Sum and Outlier; SNPs, single nucleotide 
polymorphisms.
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resulted in an OR for diabetes of 0.86 (p=0.079), indi-
cating no causal effect.
Strengths and limitations
Contrary to observational studies and RCTs for PA, the 
major advantage of our study is the use of MR, which 
has the ability to reflect lifelong exposure to a causal 
factor that might differ from self- reported PA habits or 
PA interventions for shorter time periods later in life. 
A further advantage of our study is the two- sample MR 
study design, diminishing unobserved confounding and 
reverse causality. The very large sample size (almost 900 
000 individuals in the type 2 diabetes outcome study, 
almost 500 000 individuals for PA) provided the power 
to detect effect sizes previously reported in observational 
studies and to perform multiple sensitivity analyses for 
testing the validity of the MR assumptions, thus mini-
mizing the possibility of biased results. Our study also has 
limitations. Because only data from European popula-
tions was used, our findings may differ in other ethnic-
ities. The outcome type 2 diabetes may be affected by a 
degree of misclassification because case ascertainment in 
the studies included in the DIAGRAM Consortium was 
not carried out according to certain specifications and 
thus a broad spectrum of type 2 diabetes cases (those with 
or without complications, different disease durations and 
so on) was included. The appeal of accelerometers to 
objectively monitor PA is their ability to quantify ambula-
tory activity during walking, jogging and so on. However, 
accelerometers are not without limitations. The disadvan-
tages of accelerometers are their difficulties to measure 
posture and sedentary, light activites and non- ambulatory 
activites (cycling and weightlifting), and for estimating 
energy expenditure.49 Furthermore, awareness that PA is 
being monitored might influence habitual behavior.50
CONCLUSIONS
In summary, the present two- sample MR study found 
no evidence of a causal association between genetically 
determined objectively measured PA and SB with the risk 
of type 2 diabetes and glycemic traits. There is no ques-
tion that PA has a positive impact on health, but it seems 
that the complex interplay of the numerous metabolic 
effects and multiple biological mechanisms mediating 
the beneficial role of PA on disease development51 are 
not fully understood so far. Further studies are necessary 
to deepen our understanding of the biological pathways 
of PA.
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